United Therapeutics (NASDAQ:UTHR) EVP Paul Mahon Sells 8,300 Shares

United Therapeutics Corporation (NASDAQ:UTHR) EVP Paul Mahon sold 8,300 shares of the stock in a transaction dated Thursday, March 5th. The shares were sold at an average price of $483.16, for a total transaction of $4,010,228.00. Following the completion of the transaction, the executive vice president directly owned 36,844 shares in the company, valued at $17,801,547.04. The trade was a 18.39% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.

United Therapeutics Stock Performance

Shares of UTHR stock traded down $5.15 during midday trading on Thursday, hitting $485.06. 420,755 shares of the company were exchanged, compared to its average volume of 381,036. United Therapeutics Corporation has a 52 week low of $266.98 and a 52 week high of $537.19. The firm has a market capitalization of $21.26 billion, a P/E ratio of 17.39, a PEG ratio of 1.79 and a beta of 0.84. The firm’s 50 day moving average price is $483.67 and its two-hundred day moving average price is $450.90.

United Therapeutics (NASDAQ:UTHR) last issued its quarterly earnings data on Wednesday, February 25th. The biotechnology company reported $7.70 earnings per share (EPS) for the quarter, topping the consensus estimate of $6.78 by $0.92. United Therapeutics had a net margin of 41.94% and a return on equity of 19.30%. The firm had revenue of $790.20 million during the quarter, compared to the consensus estimate of $814.80 million. During the same period last year, the business posted $6.19 earnings per share. The business’s revenue for the quarter was up 7.4% compared to the same quarter last year. Analysts expect that United Therapeutics Corporation will post 24.48 EPS for the current year.

Institutional Trading of United Therapeutics

Several large investors have recently modified their holdings of UTHR. Torren Management LLC acquired a new position in United Therapeutics in the fourth quarter valued at about $26,000. Activest Wealth Management increased its holdings in United Therapeutics by 1,400.0% in the 4th quarter. Activest Wealth Management now owns 60 shares of the biotechnology company’s stock valued at $29,000 after buying an additional 56 shares during the period. Entrust Financial LLC acquired a new position in shares of United Therapeutics in the 4th quarter valued at approximately $31,000. Wilmington Savings Fund Society FSB raised its position in shares of United Therapeutics by 125.6% in the 3rd quarter. Wilmington Savings Fund Society FSB now owns 88 shares of the biotechnology company’s stock valued at $37,000 after buying an additional 49 shares in the last quarter. Finally, Harbor Capital Advisors Inc. bought a new stake in shares of United Therapeutics during the 4th quarter worth approximately $48,000. 94.08% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several research firms recently issued reports on UTHR. HC Wainwright boosted their price target on United Therapeutics from $525.00 to $600.00 and gave the company a “buy” rating in a research note on Thursday, February 26th. Wells Fargo & Company boosted their target price on shares of United Therapeutics from $423.00 to $466.00 and gave the company an “equal weight” rating in a research report on Thursday, February 26th. UBS Group boosted their target price on shares of United Therapeutics from $655.00 to $705.00 and gave the company a “buy” rating in a research report on Thursday. TD Cowen upped their price target on shares of United Therapeutics from $525.00 to $575.00 and gave the company a “buy” rating in a research note on Wednesday, February 25th. Finally, Oppenheimer raised their price target on shares of United Therapeutics from $575.00 to $600.00 and gave the stock an “outperform” rating in a research report on Thursday, February 26th. Nine investment analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $539.00.

United Therapeutics Company Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.